AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
proglumide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cholecystokinine antagonists, antiulcer, anxiolytic agents | 2281 | 6620-60-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.20 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PLK1,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 42 | |||
| kinase-selectivity-class | AXL,BRAF,EIF2AK3,GRK2 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BX06 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
| MeSH PA | D000897 | Anti-Ulcer Agents |
| MeSH PA | D005765 | Gastrointestinal Agents |
| CHEBI has role | CHEBI:35482 | opioid analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:48873 | cholinergic antagonist |
| CHEBI has role | CHEBI:49103 | drug metabolite |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:64054 | δ-opioid receptor agonist |
| CHEBI has role | CHEBI:73296 | cholecystokinin antagonist |
| CHEBI has role | CHEBI:76206 | xenobiotic metabolite |
Related Drugs by ATC class:
A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.19 | acidic |
| pKa2 | 13.51 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Gastrin/cholecystokinin type B receptor | GPCR | ANTAGONIST | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Histamine H2 receptor | GPCR | IC50 | 2.60 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000170242 | NUI |
| D01818 | KEGG_DRUG |
| C0033321 | UMLSCUI |
| CHEBI:32058 | CHEBI |
| CHEMBL316561 | ChEMBL_ID |
| DB13431 | DRUGBANK_ID |
| D011377 | MESH_DESCRIPTOR_UI |
| 4922 | PUBCHEM_CID |
| 893 | IUPHAR_LIGAND_ID |
| 2161 | INN_ID |
| EPL8W5565D | UNII |
| 8730 | RXNORM |
| 006165 | NDDF |
| EPL8W5565D | INXIGHT DRUGS |
Pharmaceutical products:
None